THE ABBVIE 2.0 PLAYBOOK: MERCK & BMS 2026 OUTLOOK
Thesis: We are repeating the AbbVie maneuver. Between 2025 and 2030, the industry faces a $236 billion patent cliff. However, 2026 is the year the market stops fearing the loss and starts pricing the replacement. We are shifting exposure to the "Catchers"—firms with massive cash flow and a mandate to buy their way across the bridge.
I. Merck (MRK): oncology Backbone to Metabolic Powerhouse
- The "Slope" vs. The Cliff: The 2028 Keytruda cliff is being mitigated by Keytruda Qlex (SC), approved in late 2025. It is expected to capture $7B+ in annual revenue by 2030, turning a sharp drop into a manageable slope.
- The New Growth Pillar: The Moderna/Merck Cancer Vaccine (V940) Phase 3 data (expected H2 2026) is the primary rerating catalyst.
- Valuation: Trading at ~11x forward earnings, essentially pricing in a terminal decline that the subcutaneous and vaccine pipelines are currently disproving.
II. Bristol Myers Squibb (BMY): The Value Floor
- Capital Discipline: After the 2024-2025 acquisition spree, BMY has optimized its balance sheet.
- Launch Momentum: 2026 is the "prove it" year for Cobenfy (schizophrenia) and Milvexian (AFib).
- Yield Support: At a ~9x P/E floor and a ~4.6% yield, the downside is protected by a "paid-to-wait" narrative.